scholarly journals Low Dialysate Calcium: Between Low Arterial Calcification and Improved Low Bone Turnover

2016 ◽  
Vol 42 (1) ◽  
pp. 1-2 ◽  
Author(s):  
Mario Cozzolino ◽  
Stefano Carugo
Keyword(s):  
Bone Turnover ◽  
Arterial Calcification ◽  
Low Bone Turnover ◽  
Dialysate Calcium

scholarly journals The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Nai-Ching Chen ◽  
Chih-Yang Hsu ◽  
Chien-Liang Chen
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Bone Turnover ◽  
Cardiovascular Risk Factors ◽  
Vascular Calcification ◽  
Sodium Thiosulfate ◽  
Pressure Control ◽  
Arterial Calcification ◽  
Low Bone Turnover ◽  
High Bone

The high prevalence of arterial calcification in end-stage renal disease (ESRD) is far beyond the explanation by common cardiovascular risk factors such as aging, diabetes, hypertension, and dyslipidemia. The finding relies on the fact that vascular and valvular calcifications are predictors of cardiovascular diseases and mortality in persons with chronic renal failure. In addition to traditional cardiovascular risk factors such as diabetes mellitus and blood pressure control, other ESRD-related risks such as phosphate retention, excess calcium, and prolonged dialysis time also contribute to the development of vascular calcification. The strategies are to reverse “calcium paradox” and lower vascular calcification by decreasing procalcific factors including minimization of inflammation (through adequate dialysis and by avoiding malnutrition, intravenous labile iron, and positive calcium and phosphate balance), correction of high and low bone turnover, and restoration of anticalcification factor balance such as correction of vitamin D and K deficiency; parathyroid intervention is reserved for severe hyperparathyroidism. The role of bone antiresorption therapy such as bisphosphonates and denosumab in vascular calcification in high-bone-turnover disease remains unclear. The limited data on sodium thiosulfate are promising. However, if calcification is to be targeted, ensure that bone health is not compromised by the treatments.

Effect of pancreas transplantation on decreased levels of circulating bone γ-carboxyglutamic acid-containing protein and osteopenia in rats with streptozotocin-induced diabetes

1992 ◽  
Vol 127 (1) ◽  
pp. 81-85 ◽  
Author(s):  
Hitoshi Ishida ◽  
Yutaka Seino ◽  
Noritaka Takeshita ◽  
Takeshi Kurose ◽  
Kazuo Tsuji ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Bone Turnover ◽  
Pancreas Transplantation ◽  
Diabetic Rats ◽  
Chronic Complications ◽  
Carboxyglutamic Acid ◽  
Low Bone Turnover ◽  
Streptozotocin Induced Diabetes ◽  
Diabetic Osteopenia

Diabetic osteopenia has been known as one of the chronic complications of diabetes mellitus, and a decrease in bone turnover has been thought to be one of the pathophysiological characteristics of this complication. In order to investigate the effect of long-term insulin therapy on low bone turnover in diabetes, pancreas transplantation was performed on streptozotocin-induced diabetic rats. Plasma levels of bone γ-carboxyglutamic acid-containing protein(osteocalcin) in untreated diabetic rats were 0.9±0.1 (mean±sem) nmol/l, significantly lower than the value of 4.2±0.6 nmol/l in control rats (p<0.01). Pancreas transplantation reversed this decrease to 6.3±1.1 nmol/l, which was not significantly different from the value in control rats. The circulating levels of calcitriol were significantly decreased in the untreated diabetic group (p<0.01), and the decrease was fully reversed by pancreas transplantation. In addition, the decreases in bone length, strength and weight were also improved by the transplantation. This evidence clearly shows that the improvement of metabolic derangements in diabetes by insulin is essential for the prevention of deterioration in diabetic osteopenia. It is possible, therefore, that insulin exerts an indirect beneficial influence through the metabolic amelioration on the decreases in bone turnover and circulating osteocalcin in diabetes mellitus, or has a direct stimulatory effect on the osteoblasts via the insulin receptor since its presence has been shown recently in osteoblastic cells.

Bone matrix hypermineralization associated with low bone turnover in a case of Nasu-Hakola disease

Bone ◽  
2019 ◽  
Vol 123 ◽  
pp. 48-55 ◽  
Author(s):  
Mohammad Shboul ◽  
Paul Roschger ◽  
Rudolf Ganger ◽  
Lefteris Paschalis ◽  
Stamatia Rokidi ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Bone Matrix ◽  
Low Bone Turnover

scholarly journals SP360DIRECT RENIN INHIBITOR ALISKIREN AMELIORATES LOW BONE TURNOVER IN DIABETIC RAT

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii232-iii233 ◽  
Author(s):  
Shunsuke Goto ◽  
Hideki Fujii ◽  
Rie Awata ◽  
Keiji Kono ◽  
Kentaro Nakai ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Renin Inhibitor ◽  
Diabetic Rat ◽  
Low Bone Turnover

A comparison of the acute effects of subcutaneous and intranasal calcitonin

1990 ◽  
Vol 78 (2) ◽  
pp. 215-219 ◽  
Author(s):  
D. P. O'Doherty ◽  
D. R. Bickerstaff ◽  
E. V. McCloskey ◽  
R. Atkins ◽  
N. A. T. Hamdy ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Nasal Spray ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Acute Effects ◽  
Intranasal Route ◽  
Low Bone Turnover ◽  
Dose Dependent

1. We studied the acute effects of intranasal and subcutaneous calcitonin in 40 patients with active Paget's disease of bone. Patients received a single dose of either 400 units of calcitonin delivered as a nasal spray, or 1, 10 or 100 units of subcutaneous calcitonin, or placebo. 2. Subcutaneous salmon calcitonin, administered at doses of 1, 10 and 100 units to nine patients with Paget's disease of bone, induced a dose-dependent fall in the serum calcium. This calcium-lowering effect was not seen with a second group of nine patients receiving placebo. 3. The lower doses of calcitonin had significant effects, and these were more pronounced in patients with lower rates of bone turnover. 4. Four hundred units of calcitonin administered as a nasal spray induced effects qualitatively similar to those seen with subcutaneous calcitonin, with an efficacy equivalent to approximately 30 units of subcutaneous calcitonin. 5. We conclude that the bioequivalence of calcitonin given by intranasal insufflation is low compared with its parenteral administration. The intranasal route may be more appropriate for managing patients with disorders associated with low bone turnover.

Sign in / Sign up

Export Citation Format

Share Document